ATROVENT
LOE ApproachingNDAINHALATIONAEROSOL, METEREDPriority Review
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
3/8 — Basic
Priority Review
ATROVENT by Boehringer Ingelheim is (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. First approved in 1986.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATROVENT is an inhaled anticholinergic (parasympatholytic) agent approved in 1986 that works by blocking acetylcholine at muscarinic receptors on bronchial smooth muscle, preventing increases in intracellular calcium that would otherwise cause airway constriction. It is delivered via metered-dose aerosol inhaler and is indicated for maintenance treatment of bronchospasm associated with COPD. The drug represents a foundational mechanism class in respiratory medicine with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating transition from growth to managed decline and potential team restructuring.
Mechanism of Action
(parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Started Jun 2003
200 enrolled
Pulmonary Disease, Chronic Obstructive
Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
Started Dec 2002
230 enrolled
Cold
Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva
Started Oct 2002
65 enrolled
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Started Sep 2002
132 enrolled
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease
Started Jun 2001
50 enrolled
Pulmonary Disease, Chronic Obstructive
Worked on ATROVENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.